Clinical trials: Spinal Diseases
Amyotrophic Lateral Sclerosis
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.
- Trial name
- NCT03836716
- Testing
- Arimoclomol
- Where
- 23 sites in United States, Belgium and 9 more
- Volunteers
- 120 people
- Sponsor
- ZevraDenmark
Degenerative Disc Disease
Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating
The purpose of this combined retrospective and prospective clinical study is to examine the clinical outcomes of the ROI-C® anterior cervical interbody fusion device with VerteBRIDGE® plating to treat single level degenerative…
- Trial name
- NCT02104167
- Testing
- ROIC interbody cage with VerteBRIDGE plating
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- LDR Spine USA
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293709
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- Pfizer
Poliomyelitis, Diphtheria
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine
Subjects aged 9 to 13 years who participated in the 711866/001 study 5 years ago will be evaluated for immune persistence and will receive a combined dTpa-IPV booster dose that will be evaluated in terms of immunogenicity, safety…
- Conditions
- Poliomyelitis, Diphtheria, Tetanus, Acellular Pertussis
- Trial name
- NCT00635128
- Testing
- Boostrix-Polio
- Where
- 38 sites in Germany
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Poliomyelitis
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™
The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.
- Conditions
- Tetanus, Poliomyelitis, Haemophilus Influenzae Type b, Acellular Pertussis
- Trial name
- NCT01358825
- Testing
- Blood Sampling
- Where
- 4 sites in Norway, Sweden
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Degenerative Disc Disease
Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease
The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.
- Trial name
- NCT00589797
- Testing
- Activ-L Artificial Disc, ProDisc-L Total Disc Replacement or Charité Artificial Disc
- Where
- 17 sites in United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Aesculap Implant Systems
Ankylosing Spondylitis
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis
- Trial name
- ASLeap (NCT03350815)
- Testing
- 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
- Where
- 65 sites in United States
- Volunteers
- 322 people
- Sponsor
- Novartis Pharmaceuticals
Degenerative Disc Disease
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in…
- Trial name
- MSB-DR003 (NCT02412735)
- Testing
- Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture
- Where
- 48 sites in United States, Australia
- Volunteers
- 404 people
- Sponsor
- Mesoblast, Ltd.
Amyotrophic Lateral Sclerosis
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
- Trial name
- NCT04066244
- Testing
- BLZ945
- Where
- 4 sites in United States, Finland and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Poliomyelitis
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
- Trial name
- NCT00937404
- Testing
- Poliorix
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Axial Spondyloarthritis
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care [SOC]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).
- Trial name
- STRIKE (NCT02897115)
- Testing
- Adalimumab, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Volunteers
- 22 people
- Sponsor
- AbbVie
Muscular Atrophy, Spinal
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
- Trial name
- Rainbowfish (NCT03779334)
- Testing
- Risdiplam
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Ankylosing Spondylitis
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese…
- Trial name
- NCT00762463
- Testing
- Celecoxib, Diclofenac SR
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24…
- Trial name
- NCT00330681
- Testing
- MCI-186
- Volunteers
- 206 people
- Sponsor
- Shionogi
Degenerative Changes, Stenosis
Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.
- Conditions
- Degenerative Changes, Stenosis, Spondylosis
- Trial name
- NCT02018445
- Testing
- Posterolateral Fusion
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- SeaSpine, Inc.
Amyotrophic Lateral Sclerosis
A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a…
- Trial name
- NCT02714036
- Testing
- ibudilast
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- MediciNova
Urinary Tract Infections
Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections
The purpose of this study is to investigate the frequency of urinary tract infections with symptoms in spinal cord injured patients requiring intermittent catheterization for emptying the bladder.
- Trial name
- NCT00318591
- Testing
- SpeediCath, Conveen Uncoated
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Coloplast A/S
Chronic Low-Back Pain, Refractory Pain
Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)
The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic…
- Conditions
- Chronic Low-Back Pain, Refractory Pain, Neuropathic Pain
- Trial name
- NCT04479787
- Testing
- Spinal Cord Stimulation, Conventional Medical Management
- Where
- 30 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Devices
Psoriatic Arthritis
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).
- Trial name
- NCT02986373
- Testing
- risankizumab
- Volunteers
- 145 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
- Trial name
- SPIRIT-H2H (NCT03151551)
- Testing
- Ixekizumab, Adalimumab
- Where
- 131 sites in Argentina, Australia and 20 more
- Volunteers
- 566 people
- Sponsor
- Eli Lilly and Company